Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sancho

Showing results (261-270 of 289) with videos related to

Pageof 29
Sort By:
EMBO Reports|July 16, 2016
ALS/FTD-associated FUS activates GSK-3β to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associationsRadu Stoica, Sébastien Paillusson, Patricia Gomez-Suaga, et al.
Cell Death & Disease|July 3, 2026
Disruption of MCL1/BOK transmembrane interaction as a novel strategy to induce cell death in tumoursM Buffa, D Leiva, A Garcia-Jareño, et al.
Scientific Reports|July 16, 2020
Combined use of GM2AP and TCP1-eta urinary levels predicts recovery from intrinsic acute kidney injuryVíctor Blanco-Gozalo, Alfredo G Casanova, Sandra M Sancho-Martínez, et al.
British Journal of Haematology|December 19, 2014
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA GroupNoelia Purroy, Juan Bergua, Laura Gallur, et al.
Leukemia & Lymphoma|April 11, 2015
Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapyRuben Fernandez-Alvarez, Ana P Gonzalez-Rodriguez, M Esther Gonzalez, et al.
British Journal of Haematology|July 24, 2023
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMOA Martín García-Sancho, M Baile, G Rodríguez, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 29, 2020
Pathophysiological mechanisms underlying a rat model of triple whammy acute kidney injuryLaura Prieto-García, Laura Vicente-Vicente, Víctor Blanco-Gozalo, et al.
Bone Marrow Transplantation|September 16, 2014
Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilizationI Sánchez-Ortega, S Querol, M Encuentra, et al.
Nature Communications|June 4, 2014
ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43Radu Stoica, Kurt J De Vos, Sébastien Paillusson, et al.
British Journal of Haematology|December 6, 2018
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab eraAlfredo Rivas-Delgado, Laura Magnano, Miriam Moreno-Velázquez, et al.
Pageof 29

Showing results (261-270 of 289) with videos related to

Sort By:
Pageof 29
EMBO Reports|July 16, 2016
ALS/FTD-associated FUS activates GSK-3β to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associationsRadu Stoica, Sébastien Paillusson, Patricia Gomez-Suaga, et al.
Cell Death & Disease|July 3, 2026
Disruption of MCL1/BOK transmembrane interaction as a novel strategy to induce cell death in tumoursM Buffa, D Leiva, A Garcia-Jareño, et al.
Scientific Reports|July 16, 2020
Combined use of GM2AP and TCP1-eta urinary levels predicts recovery from intrinsic acute kidney injuryVíctor Blanco-Gozalo, Alfredo G Casanova, Sandra M Sancho-Martínez, et al.
British Journal of Haematology|December 19, 2014
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA GroupNoelia Purroy, Juan Bergua, Laura Gallur, et al.
Leukemia & Lymphoma|April 11, 2015
Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapyRuben Fernandez-Alvarez, Ana P Gonzalez-Rodriguez, M Esther Gonzalez, et al.
British Journal of Haematology|July 24, 2023
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMOA Martín García-Sancho, M Baile, G Rodríguez, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 29, 2020
Pathophysiological mechanisms underlying a rat model of triple whammy acute kidney injuryLaura Prieto-García, Laura Vicente-Vicente, Víctor Blanco-Gozalo, et al.
Bone Marrow Transplantation|September 16, 2014
Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilizationI Sánchez-Ortega, S Querol, M Encuentra, et al.
Nature Communications|June 4, 2014
ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43Radu Stoica, Kurt J De Vos, Sébastien Paillusson, et al.
British Journal of Haematology|December 6, 2018
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab eraAlfredo Rivas-Delgado, Laura Magnano, Miriam Moreno-Velázquez, et al.
Pageof 29